Laboratory of Molecular Toxicology, College of Pharmacy, Pusan National University, Jangjeon-dong, Geumjeung-gu, Busan, Republic of Korea.
Int J Med Sci. 2012;9(10):881-93. doi: 10.7150/ijms.5011. Epub 2012 Nov 7.
Tamoxifen is currently used for the treatment of estrogen receptor-positive breast cancer patients, but acquired resistance to tamoxifen is a critical problem in breast cancer therapy. Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed HDAC inhibitor. The aim of this study is to investigate the anticancer effects of SAHA in tamoxifen-resistant MCF-7 (TAMR/MCF-7) cells.
Cytotoxicity, apoptosis and autophagic cell death induced by SAHA were studied. A TAMR/MCF-7 cells xenograft model was established to investigate the inhibitory effect of SAHA on tumor growth in vivo.
SAHA inhibited the proliferation of TAMR/MCF-7 cells in a dose-dependent manner. SAHA significantly reduced the expression of HDAC1, 2, 3, 4 and 7 and increased acetylated histone H3 and H4. Although SAHA induced G2/M phase arrest of cell cycle, apoptotic cell death was very low, which is correlated with the slight change in the activation of caspases and PARP cleavage. Interestingly, expression of the autophagic cell death markers, LC3-II and beclin-1, was significantly increased in TAMR/MCF-7 cells treated with SAHA. Autophagic cell death induced by SAHA was confirmed by acridine orange staining and transmission electron microscopy (TEM) in TAMR/MCF-7 cells. In mice bearing the TAMR/MCF-7 cell xenografts, SAHA significantly reduced the tumor growth and weight, without apparent side effects.
These results suggest that SAHA can induce caspase-independent autophagic cell death rather than apoptotic cell death in TAMR/MCF-7 cells. SAHA-mediated autophagic cell death is a promising new strategy to treatment of tamoxifen-resistant human breast cancer.
他莫昔芬目前被用于治疗雌激素受体阳性的乳腺癌患者,但对他莫昔芬的获得性耐药是乳腺癌治疗中的一个关键问题。丁酸钠(SAHA)是新开发的组蛋白去乙酰化酶(HDAC)抑制剂的原型。本研究旨在研究 SAHA 对他莫昔芬耐药 MCF-7(TAMR/MCF-7)细胞的抗癌作用。
研究了 SAHA 诱导的细胞毒性、细胞凋亡和自噬性细胞死亡。建立 TAMR/MCF-7 细胞异种移植模型,以研究 SAHA 对体内肿瘤生长的抑制作用。
SAHA 呈剂量依赖性抑制 TAMR/MCF-7 细胞的增殖。SAHA 显著降低了 HDAC1、2、3、4 和 7 的表达,并增加了乙酰化组蛋白 H3 和 H4。虽然 SAHA 诱导了细胞周期的 G2/M 期阻滞,但细胞凋亡很少,这与半胱天冬酶激活和 PARP 切割的轻微变化有关。有趣的是,SAHA 处理的 TAMR/MCF-7 细胞中自噬性细胞死亡标志物 LC3-II 和 beclin-1 的表达显著增加。SAHA 在 TAMR/MCF-7 细胞中诱导的自噬性细胞死亡通过吖啶橙染色和透射电子显微镜(TEM)得到证实。在携带 TAMR/MCF-7 细胞异种移植物的小鼠中,SAHA 显著降低了肿瘤生长和重量,没有明显的副作用。
这些结果表明,SAHA 可以在 TAMR/MCF-7 细胞中诱导 caspase 非依赖性自噬性细胞死亡,而不是凋亡性细胞死亡。SAHA 介导的自噬性细胞死亡是治疗他莫昔芬耐药人乳腺癌的一种有前途的新策略。